Slide 1: Investor Presentation 1Q2026
INVESTOR PRESENTATION IMEXPHARM CORPORATION 1Q2026 1
Slide 2: 1Q2026 Business Results
” -— = =) ” Lu ~ 2) ” Lu = ” =) co © N oO N \e =
Slide 3: Market turbulence masked by robust economic growth
Market turbulence masked by robust economic growth Geopolitical Instability in the Middle East Rising logistics costs and delivery delays, coupled with surging prices for raw materials and packaging, are driving inflationary pressures Strict Regulatory Enforcement New regulations, including Res.68 (
Slide 4: Resilient performance amid a challenging start
Resilient performance amid a challenging start 1Q2026 4M2026 Gross revenue ▼ 6% yoy ▼ 11% yoy 44,7% 41,5% Gross 39,5% 40,1% 39,6% VND 629 billion VND 829 billion profit margin 16,8% Net revenue ▼ 8% yoy ▼ 12% yoy Net 12,5% 14,3% 13,4% 15,0% VND 546 billion VND 712 billion profit margin 25,8% EBITDA
Slide 5: 1Q profitability maintained through disciplined cost control
1Q profitability maintained through disciplined cost control VND bn 629,2 546,2 -83,0 226,6 -319,6 27,7 129,4 102,8 -122,9 -0,9 Gross revenue Sales deduction Net revenue COGS Gross Profit SG&A expense Others PBT Int,Dep,Amor EBITDA YoY (6.3%) 7.2% (8.1%) (11%) (3.3%) (8.7%) (80%) 7.9% (2.4%) 2.7% 5
Slide 6: Topline growth faced temporary headwinds across both ETC and OTC channels
Topline growth faced temporary headwinds across both ETC and OTC channels with recovery expected as market dynamics stabilize Gross revenue contracted across both ETC and OTC OTC channel contracted 7% yoy, achieving 23% of year-end target 1Q25 51% 48% 1% • Retail pharmacies and clinics deferred inve
Slide 7: Costs remained well-controlled, reinforcing profitability despite top-line pressure
Costs remained well-controlled, reinforcing profitability despite top-line pressure COGS (VND bn) -11% • COGS decreased by 11% YoY, outpacing the decline in gross revenue, driven by the optimized management of product- based promotions. • While raw material market prices are trending upward, the 360
Slide 8: Production by Factory
1Q production calibrated to demand and scaling in Q2 to rebuild stock 2% 308 9% 285 1Q25 Revenue by Factory 230 43% 210 1Q26 (VND Bn) 32% 1Q26 102 92 60 60 IMP1 IMP2 IMP3 IMP4 IMP1 IMP2 IMP3 IMP4 14% Others Production volume 1Q26 Factory • Revenue was down across IMP 1,2,3 and flat at the most Produ
Slide 9: Continued leading position in tier 2 Tender
Continued leading position in tier 2 Tender Market tender value IMP tender value (VND Tn) (VND Bn) 9,4 8,6 8,7 15.9% %MS 14.4% 7,9 0.5% 0.4% 0.4% 0.6% 1Q25 698,6 4,8 1Q26 547,7 3,5 1Q25 1Q26 42,2 38,1 35,4 47,6 Tier 1 Tier 2 Tier 3-5 Tier 1 Tier 2 Tier 3-5 Source: The data is for reference only, pub
Slide 10: Sustained Non-Rx momentum mitigates headwinds with tightly managed R&D pipeline
Sustained Non-Rx momentum mitigates headwinds with tightly managed R&D pipeline 10.4% 71% 29% 4.0% +1 +8 159 3.9% New SKUs New project R&D pipeline 2.8% 2.7% 3.2% 0.9% 1.0% Focus on Non-Rx Antibiotics Cough medicine Digestive aid Analgesic and antipyretic ✓ Cough and cold preparations Anti-inflammat
Slide 11: 2026 Business Plan
02 2026 Business Plan 11
Slide 12: Continued regulatory transformation enhancing industry capability and transparency
Continued regulatory transformation enhancing industry capability and transparency Decree 90/2026/ND-CP Increased penalties against: (effective 15/5/2026) • Selling Rx drugs without prescription in OTC channel Penalties for administrative • Selling non-essential Rx drug at medicine counters violatio
Slide 13: Our 2025 business guidance
Our 2025 business guidance Metric 2025 2026 No. Growth Target (VND bn) Actual Plan 1 Gross revenue 2,914 3,200 9.8% • OTC 1,271 6.5% • ETC 1,541 11.6% 2 Net revenue 2,441 10.1% 3 Profit before tax 446 502 12.5% 4 EBITDA 567 637 12.3% 5 EBITDA margin 23.2% 23.7% 0.5 pct point 13
Slide 14: Driving growth through operational excellence and margin expansion
Driving growth through operational excellence and margin expansion Revenue growth Gross margin optimization Profitability enhancement Enhancing distribution quality and Portfolio restructuring and supply Digitalization and ESG customer value chain management integration • Focus on driving sales thro
Slide 15: Thank You
Thank You For further discussion, please contact our IR team ir@imexpharm.com 15